To reduce the development of drug-resistant bacteria or fungi and maintain effectiveness, anti-infective drugs should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria or fungi.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA, please see: https://www.fda.gov/STIC.
REZZAYO®
(rezafungin for injection)
Antimicrobial Susceptibility Testing (AST)
Reference Lab Testing
Resources for Validation-Verification
VABOMERE®
(meropenem and vaborbactam) for injection
Antimicrobial Susceptibility Testing (AST)
Resources for Validation-Verification
KIMYRSA®
(oritavancin) for injection
Antimicrobial Susceptibility Testing (AST)
ORBACTIV®
(oritavancin) for injection
Antimicrobial Susceptibility Testing (AST)
MINOCIN®
(minocycline) for injection
Antimicrobial Susceptibility Testing (AST)
Resources for Validation-Verification
BAXDELA®
(delafloxacin)
Antimicrobial Susceptibility Testing (AST)
or click here to access
our online form.
Report an Adverse Event or Quality Complaint
Call 1-844-MED-MLNT(+1 844-633-6568).
You may also report suspected
adverse events to the FDA
at 1-800-FDA-1088 or
https://www.fda.gov/medwatch
Scan
Access Melinta MedicalInformation Library
NEWR Call
1-844-med-mlnt(+1 844-633-6568)
to speak with a medical
information representative